Survival prediction model for postoperative hepatocellular carcinoma patients

Zhihui Ren, PhD, Shasha He, BS, Xiaotang Fan, PhD, Fangping He, PhD, Wei Sang, BS, Yongxing Bao, PhD, Weixin Ren, PhD, Jinming Zhao, PhD, Xuewen Ji, MD, Hao Wen, PhD.*

Abstract
This study is to establish a predictive index (PI) model of 5-year survival rate for patients with hepatocellular carcinoma (HCC) after radical resection and to evaluate its prediction sensitivity, specificity, and accuracy.

Patients underwent HCC surgical resection were enrolled and randomly divided into prediction model group (101 patients) and model evaluation group (100 patients). Cox regression model was used for univariate and multivariate survival analysis. A PI model was established based on multivariate analysis and receiver operating characteristic (ROC) curve was drawn accordingly. The area under ROC (AUROC) and PI cutoff value was identified.

Multiple Cox regression analysis of prediction model group showed that neutrophil to lymphocyte ratio, histological grade, microvascular invasion, positive resection margin, number of tumor, and postoperative transcatheter arterial chemoembolization treatment were the independent predictors for the 5-year survival rate for HCC patients. The model was PI = 0.377 × NLR + 0.554 × HG + 0.927 × PRM + 0.778 × MVI + 0.740 × NT – 0.831 × transcatheter arterial chemoembolization (TACE). In the prediction model group, AUROC was 0.832 and the PI cutoff value was 3.38. The sensitivity, specificity, and accuracy were 78.0%, 80%, and 79.2%, respectively. In model evaluation group, AUROC was 0.822, and the PI cutoff value was well corresponded to the prediction model group with sensitivity, specificity, and accuracy of 85.0%, 83.3%, and 84.0%, respectively.

The PI model can quantify the mortality risk of hepatitis B related HCC with high sensitivity, specificity, and accuracy.

Abbreviations: AUROC = the area under receiver operating characteristic, HCC = hepatocellular carcinoma, HG = histological grade, MTS = maximum tumor size, MVI = microvascular invasion, NLR = neutrophil-to-lymphocyte ratio, NT = number of tumor, PI = predictive index, PRM = positive resection margin, ROC = receiver operating characteristic, TACE = transcatheter arterial chemoembolization.

Keywords: Cox regression model, hepatocellular carcinoma, postoperative transcatheter arterial chemoembolization, radical resection, survival analysis

1. Introduction
Hepatocellular carcinoma (HCC) is one of the world’s most common malignancies, with more than 750,000 new cases each year.[1] It also ranked the third among the mortality rate of all cancers,[2] and more than 55% HCC were in China because of the high rate of hepatic B infection.[3]

HCC resection and liver transplantation is of high efficacy for patients with early HCC.[4,5] Liver transplantation is seldom performed because of limited liver donor, therefore, liver resection remains the most widely used radical HCC treatment. Other treatments, including radiofrequency, interventional therapy, immune enhancement, molecularly targeted therapies, traditional medicine, can serve as complement to further improve the survival rate.[6-7]

Complete removal of the tumor is essential in HCC recurrence reduction and survival improvement. The pathology diagnosis of surgical margin is still the gold standard to determine whether surgical resection is completed. Those with positive resection margin (PRM) usually come with poor prognosis[8] and significantly higher recurrence rate compared with non-PRM patients, probably because of the postoperative residual micro-metastases.

Second, HCC histological grade (HG) can reflect the HCC biological characteristics. Poor differentiation indicates high malignancy, that is, patients with poor differentiation usually have lower average disease-free survival and lower overall survival rate compared patients with high differentiation.[9–11]

The HCC survival time is closely related with microvascular invasion (MVI) in resected HCC tissue.[12] and MVI is one of the prediction markers of intrahepatic micrometastases and HCC recurrence.[12] Positive MVI in HCC tissue pathology suggested...
intrahepatic and extrahepatic metastasis that led to poor prognosis. It is worth noting that lymph node metastasis is also listed as one of MVI presentations.

Patients with multiple intrahepatic HCC are often of high recurrence rate and postoperative mortality after surgical resection. Even if the pathology of surgical margins are negative, microsatellite lesions, and MVI could be detected. Except for only a few cases, multiple HCCs are all intrahepatic metastasis that surgery cannot achieve radical resection. Therefore, surgical resection is not recommended for patients with HCC of equal or more than 3 lesions. HCC is of higher postoperative recurrence rate and metastasis rate, and lower 5-year survival rate. Therefore comprehensive treatment is commonly recommended. However, the effectiveness of various treatments still requires further investigation. For example, whether transcatheter arterial chemoembolization (TACE) should be routinely used as postoperative prevention remains controversial. TACE may cause various degrees of hepatic injury that would lead to poor prognosis. In recent years, TACE is advancing by using safer chemotherapy drugs and highly selective blood clots to optimize the benefits and reduce liver damage of interventional therapy. Currently, there are each time more reports on the benefits of prophylactic TACE treatment after surgery for its safe and effective improvement for HCC patients’ prognosis. Chen et al showed that prophylactic TACE performed in postoperative 1 or 2 month would reduce recurrence rate; however, multiple TACE may increase liver damage and affect the survival rate. Yang et al showed that TACE could significantly improve the prognosis of HCC patients with Child–Pugh A level. In summary, the benefit of TACE for HCC patients required more evidence-based research.

Lymphopenia would reduce T lymphocyte-mediated tumor cell killing effect, and the increased neutrophils would result in release of systemic cytokines, such as chemokines and interleukin, leading to persistent inflammation, tumor cell proliferation, and angiogenesis. Increased neutrophil-to-lymphocyte ratio (NLR) indicates the imbalance of the immune response to cancer and the body’s immune system. Therefore, NLR is widely accepted as marker of poor prognosis. However, there are no quantitative measures for the effects of immune imbalance on HCC prognosis. In this study, prediction model is established to quantify the risk impact on HCC prognosis.

2. Patients and methods

2.1. Subjects

HCC patients admitted in Xinjiang Medical College First Hospital from October 2007 to October 2010 were recruited. Patients with complete clinical recording and follow-up data were included in the final analysis. All patients had HCC on the basis of chronic hepatitis B infection and cirrhosis who underwent surgical resection. Patients were excluded if they had preoperative HCC with extensive intrahepatic or distant metastasis; no major invasions of surrounding organs and vessels; other malignancies; Child–Pugh class C; major diseases, such as cardiovascular diseases, and respiratory diseases. Patients were followed up from surgical resection until 5 years or death. Prior written and informed consent were obtained from every patient and the study was approved by the ethics review board of the First Affiliated Hospital of Xinjiang Medical University.

2.2. Outcome measurements

The surgical margin is defined positive if any one of the below was positive: microinvasion was detected on surgical margin; abnormal cell growth or precancerous lesions were detected on surgical margin; surgical margins were of less than 0.5 mm from the foci. The survival rate was measured from the date of surgery to date of death or last follow-up. Postoperative TACE was the independent protective factor with significantly impacted prognosis (Table 3). Among these 6 factors, 5 factors were the independent risk factors, namely NLR, HG, MVI, MTS, and Child–Pugh class A/B.

2.3. Statistical analysis

SPSS19.0 (SPSS Inc, Chicago, IL) was used for statistical analysis. Univariate and multivariate Cox regression analysis and maximum likelihood method was used to establish predictive index (PI) model. ROC curve was drawn accordingly. The area under ROC and PI cutoff value was identified, combined with sensitivity, specificity, and accuracy value, to evaluate the predictive value of PI model. P<.05 was considered statistically significant.

3. Results

3.1. Characteristics of patients in the 2 groups

There were 201 patients finally included in the study, and patients were randomly divided into prediction model group (101 patients) and model evaluation group (100 patients). There were 130 males (64.7%) and 71 females (35.3%). Their age ranged from 38 to 69 years, with median age of 43 years. The survival time was 7 to 60 months, with median survival time of 25 months. There were 81 cases (40.3%) died during the 5-year follow-up, including 41 cases (40.6%) in prediction model group and 40 cases (40.0%) in model evaluation group. There were no significant difference between age, sex, and major blood indicators between prediction model group and model evaluation group (P>.05) (Table 1).

3.2. Univariate Cox regression analysis

To determine early prediction factors of postoperative HCC survival, univariate Cox regression analysis was performed. Univariate Cox regression analysis showed that 9 factors had significant differences in 5-year survival, namely, NLR, cirrhosis, MVI, maximum tumor size (MTS), number of tumor (NT), HG, tumor capsule, PRM, and postoperative TACE (P<.05) (Table 2). The results indicate that NLR, cirrhosis, MVI, MTS, NT, HG, tumor capsule, PRM, and postoperative TACE may be used as prediction factors for postoperative HCC survival.

3.3. Multivariate Cox regression analysis

To further determine the independent prediction factors of postoperative HCC survival, multivariate Cox regression analysis was performed. Taken the 9 factors into the multivariate Cox regression model, there were 6 factors that significantly impacted prognosis (Table 3).
### Table 1
Comparison of baseline characteristics of HCC patients between prediction model group and model evaluation group.

|                          | Prediction model group (n=101) | Model evaluation group (n=100) | P    |
|--------------------------|--------------------------------|--------------------------------|------|
| Sex (male/female)        | 64/37                          | 66/34                          | .696 |
| Age, y                   | 49                             | 51                             | .183 |
| Smoking                  | 56/45                          | 43/57                          | .078 |
| Drinking                 | 53/48                          | 55/45                          | .720 |
| NLR                      | 4.31 ± 1.03                    | 4.36 ± 1.41                    | .792 |
| Hb, g/L                  | 113 ± 19                       | 114 ± 22                       | .718 |
| AFP, ng/mL               |                                |                                | .101 |
| > 300                    | 66                             | 54                             |      |
| < 300                    | 35                             | 46                             |      |
| Hepatitis B DNA load, copies/mL |                    |                                | .433 |
| > 5.00E+02               | 52                             | 57                             |      |
| < 5.00E+02               | 49                             | 43                             |      |
| Prealbumin, g/L          | 132 ± 33                       | 140 ± 27                       | .075 |
| Ccr, μmol/L              | 63 ± 23                        | 79 ± 18                        | .212 |
| ALT, U/L                 | 96 ± 57                        | 81 ± 66                        | .090 |
| AST, U/L                 | 73 ± 25                        | 66 ± 38                        | .147 |
| ApoA, g/L                | 1.24 ± 0.34                    | 1.21 ± 0.33                    | .530 |
| ApoB, g/L                | 0.91 ± 0.14                    | 0.93 ± 0.29                    | .800 |
| TC, mmol/L               | 2.75 ± 1.97                    | 3.23 ± 1.85                    | .072 |
| TG, mmol/L               | 1.36 ± 0.38                    | 1.29 ± 0.35                    | .170 |
| HDL, mmol/L              | 1.46 ± 0.23                    | 1.44 ± 0.23                    | .435 |
| LDL, mmol/L              | 2.95 ± 0.22                    | 2.95 ± 0.22                    | .314 |
| TBL, μmol/L              | 36.27 ± 9.47                   | 35.85 ± 10.80                  | .767 |
| PTA, %                   | 90 ± 18                        | 89 ± 14                        | .510 |
| Albumin, g/L             | 46.45 ± 8.24                   | 45.23 ± 6.24                   | .236 |
| GGTT, U/L                | 123 ± 42                       | 130 ± 49                       | .272 |
| Child Pugh class (A, B)  |                                |                                | .858 |
| A level                  | 87                             | 87                             |      |
| B level                  | 14                             | 13                             |      |

### Table 2
Univariate Cox regression analysis of 5-year survival rate for postoperative HCC patients.

|                | β     | Standard error | Wald value | Degree of freedom | P     | OR  | 95% CI         |
|----------------|-------|----------------|------------|-------------------|-------|-----|---------------|
| NLR            | 0.51  | 0.17           | 9.12       | 1                 | .003  | 1.66| 1.20–2.30     |
| Cirrhosis      | 0.65  | 0.33           | 3.85       | 1                 | .050  | 1.91| 1.00–3.64     |
| Tumor capsule  | 0.69  | 0.32           | 4.77       | 1                 | .029  | 1.99| 1.07–3.69     |
| MTS            | 0.79  | 0.32           | 6.19       | 1                 | .013  | 2.20| 1.18–4.10     |
| MVI            | 0.96  | 0.31           | 9.24       | 1                 | .002  | 2.60| 1.40–4.82     |
| NT             | 0.65  | 0.31           | 4.28       | 1                 | .038  | 1.91| 1.04–3.53     |
| PMI            | 0.62  | 0.32           | 3.90       | 1                 | .048  | 1.86| 1.00–3.46     |
| Postoperative TACE | – 0.95 | 0.35   | 7.22       | 1                 | .007  | 0.39| 0.19–0.77     |
| HG             | 0.43  | 0.20           | 4.78       | 1                 | .029  | 1.53| 1.05–2.24     |

C = confidence interval, HCC = hepatocellular carcinoma, ALT = alanine transaminase, ApoA = apolipoprotein A1, ApoB = apolipoprotein, AST = aspartate transaminase, Ccr = creatinine clearance rate, GGTT = gamma-glutamyl transpeptidase, HCC = hepatocellular carcinoma, HDL = high density lipoprotein, LDL = low density lipoprotein, NLR = neutrophil to lymphocyte ratio, PTA = prothrombin time activity percentage, TBL = total bilirubin, TC = total cholesterol, TG = triglyceride.

### Table 3
Multivariate Cox regression analysis of 5-year survival rate for postoperative HCC patients.

|                | β     | Standard error | Wald value | Degree of freedom | P     | OR  | 95% CI         |
|----------------|-------|----------------|------------|-------------------|-------|-----|---------------|
| NLR            | 0.377 | 0.19           | 3.93       | 1                 | .047  | 1.46| 1.00–2.12     |
| MVI            | 0.776 | 0.36           | 4.71       | 1                 | .030  | 2.18| 1.08–4.39     |
| NT             | 0.740 | 0.32           | 5.34       | 1                 | .021  | 2.10| 1.12–3.93     |
| PMI            | 0.927 | 0.34           | 7.53       | 1                 | .006  | 2.53| 1.30–4.90     |
| Postoperative TACE | – 0.831 | 0.37 | 5.13       | 1                 | .023  | 0.44| 0.21–0.89     |
| HG             | 0.554 | 0.21           | 6.77       | 1                 | .009  | 1.74| 1.15–2.64     |

C = confidence interval, HCC = hepatocellular carcinoma, HG = tumor histological grade, MVI = microvascular invasion, NLR = neutrophil to lymphocyte ratio, NT = number of tumor, OR = odds ratio, PMI = positive resection margin; TACE = transcatheter arterial chemoembolization.
OR of 0.44 (P < .05). There were no significant differences in factors of cirrhosis, MTS, and tumor capsule in the multivariate analysis. Thus, they were not independent factors for the 5-year survival.

### 3.4. PI model and its predictive value

To determine the weight of independent prediction factors of postoperative HCC survival, PI model was established. The PI model was established based on multivariate analysis: PI = 0.377 x NLR + 0.554 x HG (high = 1, medium = 2, low = 3) + 0.927 x PRM (yes = 1, no = 0) + 0.778 x MVI (yes = 1, no = 0) + 0.740 x NT (single = 0, multiple = 1) - 0.831 x TACE (yes = 1, no = 0). The PI was between 0.73 and 5.65. The greater the PI is, the worse the prognosis would be.

Figure 1 showed that the area under ROC (AUROC) was 0.832 (0.753–0.911) with statistical significance (P < .05). PI cutoff value was 3.38. HCC = hepatocellular carcinoma, ROC = receiver operating characteristic.

### Figure 1.

ROC curve for prediction of 5-year survival rate for postoperative HCC patients in prediction model group. The area under ROC (AUROC) was 0.832 (0.753–0.911) with statistical significance (P < .05). PI cutoff value was 3.38. HCC = hepatocellular carcinoma, ROC = receiver operating characteristic.

Table 4

| Number (cases) | Survival (cases) | Death (cases) | Sensitivity (%) | Specificity (%) | Positive predictive value (%) | Negative predictive value (%) | Accuracy (%) | AUROC |
|----------------|------------------|---------------|-----------------|-----------------|------------------------------|-------------------------------|--------------|-------|
| ≥3.38          | 44               | 12            | 32              | —               | —                            | —                             | —            | (0.753–0.911) |
| <3.38          | 57               | 48            | 9               | —               | —                            | —                             | —            |       |
| Total          | 101              | 60            | 41              | 78.0            | 80.0                         | 72.7                          | 84.2         | 79.2  | 0.832 |

AUROC = the area under receiver operating characteristic.
diameter of 5 cm as the cutoff point. For patients with tumor diameter of more than 5 cm, there were no significant differences in 5-year survival compared with that of diameter less than 5 cm when other factors were adjusted. However, as tumor diameter increased, MVI, PRM and NLR would accordingly increase, thus tumor diameter may still be an important factor.

In accordance with previous studies,[12,40] MVI, NT, and PRM were independent risk factors for postoperative HCC 5-year survival rate with high weight in the risk prediction model. In fact, HCC with large tumor size is more likely to have MVI and PRM,[22,23] suggesting the importance of surgery optimization.

The increased NLR reflected the body’s reduced tumor-specific immune response to cancer and immunity imbalance.[36] Consistently, our result showed that NLR was an independent risk factor for 5-year survival of HCC patients. Multivariate Cox regression showed that postoperative TACE treatment was an independent protective factor for the 5-year survival rate with high significance. Therefore, at least 1 TACE is recommended for HCC patients after surgery. If patients with multiple risk factors, such as poorly differentiated HCC, PRM, multiple tumors, MVI, and satisfactory liver function, 3 TACE treatments and more frequent follow-ups are recommended.[18] The OR of TACE was 0.44 in our study, suggesting its great benefit to improve the prognosis.

In our study, NT was also the independent risk factor for 5-year survival rate. Patients with multiple liver tumors are often associated with higher recurrence rate and postoperative mortality.[13,40] Histological tumor microsatellite lesions and MVI are often observed even if postoperative pathology shows negative margins.[18,41] In addition, except for only a few cases, multiple HCCs are all intrahepatic metastasis that surgery cannot achieve radical resection, as reported previously.[20–23] This study has some limitations. First, we did not include the tumor markers (such as AFP, DCP, and AFP L3%) of HCC in the prediction model. The influences of tumor markers on the prediction model are unknown. Second, the influence of the etiology of underlying liver cirrhosis on the prediction model was not analyzed.

To sum up, based on the PI model above, patients with PI ≥ 3.38 showed poor prognosis and the AUROC were 0.832 and 0.822 for prediction model group and model evaluation group, respectively. Our findings may provide evidence for clinicians to predict 5-year survival rate based on clinical information and to make individualized treatment strategy accordingly.

References
[1] Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011;61:69–90.
[2] Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277–300.
[3] Zhang XF, Qi X, Meng B, et al. Prognosis evaluation in alpha-fetoprotein negative hepatocellular carcinoma after heptectomy: comparison of five staging systems. Eur J Surg Oncol 2010;36:718–24.
[4] Roayaie S, Blume IN, Thung SN, et al. A system of classifying microvascular invasion to predict outcome after resection in patients with hepatocellular carcinoma. Ann Surg 2007;245:831–4.
[5] Lo CM, Liu CL, Chan SC, et al. A randomized, controlled trial of transcatheter arterial chemoembolization for the patients with primary hepatocellular carcinoma. J Hepatobiliary Surg 2015;39:1134–41.
[6] Roayaie S, Blume IN, Thung SN, et al. A system of classifying microvascular invasion to predict outcome after resection in patients with hepatocellular carcinoma. Ann Surg Oncol 2008;15:1375–82.
[7] Hua YF, Lu CD, Qiu F, et al. Transcatheter arterial chemoembolization of primary dea liver cell carcinoma of the liver. Zhonghua Zhong Liu Za Zhi 2013;35:140–3.
[8] Wang L, Wu F, Wu J, et al. Analysis of risk factors of recurrence of hepatocellular carcinoma after control of surgical-risk-factors. Zhonghua Zhong Liu Za Zhi 2014;36:929–34.
[9] Shah SA, Cleary SP, Wei AC, et al. Recurrence after liver resection for hepatocellular carcinoma: risk factors, treatment, and outcomes. Surgery 2007;141:330–9.
[10] Sumie S, Kuromatsu R, Okuda K, et al. Micrvascular invasion in patients with hepatocellular carcinoma and its predictable clinicopathological factors. Ann Surg Oncol 2008;15:1375–82.
[11] Lo CM, Liu CL, Chan SC, et al. A randomized, controlled trial of postoperative adjuvan interferon therapy after resection of hepatocellular carcinoma. Ann Surg 2007;245:831–42.
[12] Hoshida Y, Villanueva A, Kobayashi M, et al. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med 2008;359:1999–2004.
[13] Wang BH, Lau WY, Leung T, et al. Hematogenous dissemination of hepatocytes and tumor cells after surgical resection of hepatocellular carcinoma: a quantitative analysis. Clin Cancer Res 1999;5:4021–7.
[14] Zhang J, Gong SJ, Wang ZS, et al. The survival analysis of hepatocellular carcinoma with portal vein tumor thrombosis treated with transarterial chemoembolization. Chinese J Clinicians (Electronic Edition) 2013;7:4731–3.
[15] Hua YF, Lu CD, Qiu F, et al. Transcatheter arterial chemoembolization after liver resection for hepatocellular carcinoma with portal vein tumor thrombus. Zhonghua Gan Dan Wai Ke Za Zhi 2012;18:357–60.
[16] Zhu Q, Qiao GL, Yan JJ, et al. Prognosis after resection of early hepatocellular carcinoma in HBV-related cirrhotic patients. Zhonghua Gan Dan Wai Ke Za Zhi 2014;20:238–64.
[17] Wang XL, Yang J, FD, Lu ZT, et al. Clinical study of the prognosis of primary liver cancer after resection. Chinese J Clinicians (Electronic Edition) 2013;7:39–43.
[24] Wu ZQ. Operation indication and operation choice for liver cancer. Zhonghua Gan Dan Wai Ke Za Zhi 2002;8:137–9.

[25] Liu PY, Liu RH, Xu H, et al. Significance of preventive TACE in primary liver cancer after operation. Zhonghua Gan Dan Wai Ke Za Zhi 2003;11:81–2.

[26] Lu W, Li YH, Yu ZJ, et al. A comparative study of damage to liver function after TACE with use of low-dose versus conventional-dose of anticancer drugs in hepatocellular carcinoma. Hepatogastroenterology 2007;54:1499–502.

[27] Vogl TJ, Naguib NN, Nour-Eldin NE, et al. Review on transarterial chemoembolization in hepatocellular carcinoma: palliative, combined, neoadjuvant, bridging, and symptomatic indications. Eur J Radiol 2009;72:505–16.

[28] Chung GE, Lee JH, Kim HY, et al. Transarterial chemoembolization can be safely performed in patients with hepatocellular carcinoma invading the main portal vein and may improve the overall survival. Radiology 2011;258:627–34.

[29] Luo J, Guo RP, Lai EC, et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma with portal vein tumor thrombus: a prospective comparative study. Ann Surg Oncol 2011;18:413–20.

[30] Niu ZJ, Ma YL, Kang P, et al. Transarterial chemoembolization compared with conservative treatment for advanced hepatocellular carcinoma with portal vein tumor thrombus: using a new classification. Med Oncol 2012;29:2992–7.

[31] Jiang HZ, Deng X, Zhong YF. TACE treatment for liver cancer with portal vein tumor thrombus. Zhonghua Pu Tong Wai Ke Za Zhi 2015;24:116–20.

[32] Yao HX, Wang C, Li DJ, et al. TACE combined with radiotherapy for hepatocellular carcinoma with portal thrombus. Zhonghua Pu Tong Wai Ke Za Zhi 2012;21:893–5.

[33] Sansonno D, Laulettta G, Russi S, et al. Transarterial chemoembolization plus sorafenib: a sequential therapeutic scheme for HCV-related intermediate-stage hepatocellular carcinoma: a randomized clinical trial. Oncologist 2012;17:359–66.

[34] Cheng SQ, Wu MC. Advancement in comprehensive treatment of primary hepatocellular carcinoma. Zhonghua Gan Dan Wai Ke Za Zhi 2009;15:241–3.

[35] Yang HJ, Guo Z, Jiang JH. A study on factors influencing survival of 274 BCLC stage A HCC patients treated with transarterial chemoembolization. Zhonghua Pu Tong Wai Ke Za Zhi 2015;30:185–8.

[36] Pinato DJ, Sharma R. An inflammation-based prognostic index predicts survival advantage after transarterial chemoembolization in hepatocellular carcinoma. Transl Res 2012;160:146–52.

[37] Chinese Society of Hepatology and Chinese Society of Infectious Diseases CMAThe guideline of prevention and treatment for chronic hepatitis B (2010 version). Zhonghua Gan Zang Bing Za Zhi 2011;19:13–24.

[38] Sun HC, Zhang W, Qin LX, et al. Positive serum hepatitis B e antigen is associated with higher risk of early recurrence and poorer survival in patients after curative resection of hepatitis B-related hepatocellular carcinoma. J Hepatol 2007;47:684–90.

[39] He SS, Fan XT, Zhu D, et al. Establishment of predictive index model for postoperative survival in patients with hepatitis B-related hepatocellular carcinoma. Zhonghua Pu Tong Wai Ke Za Zhi 2013;24:952–7.

[40] Poon RT, Ng JO, Fan ST, et al. Clinicopathologic features of long-term survivors and disease-free survivors after resection of hepatocellular carcinoma: a study of a prospective cohort. J Clin Oncol 2001;19:3037–44.

[41] Kim JH, Yoon HK, Ko GY, et al. Nonsresectable combined hepatocellular carcinoma and cholangiocarcinoma: analysis of the response and prognostic factors after transcatheter arterial chemoembolization. Radiology 2010;255:270–7.